Future directions in genetic strategies for understanding and treating idiopathic pulmonary fibrosis

Adriana Heguy, Rana Kaplan, Ronald Crystal

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Insights into the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the strategies for treatment of this disorder have evolved over the past 30 years. In the pregenetic era, prior to the early 1970s, the pathogenesis and treatment of IPF was based on classic clinical and pathological assessments. In this period, the disease was defined on a clinical level, with the natural history, clinical presentation, blood chemistry, radiographic features, and morphology of the disorder understood (1–5). In what can be called the early genetic era, from the late 1970s to the present, as the newly developed technologies of mammalian molecular biology, cell biology, and culture were applied to lung disease, IPF was understood to be an inflammatory disorder with superimposed dysfunction of lung repair mechanisms, and new approaches to therapy were developed (6–10). In the current genetic era, with the sequencing of the human and murine genomes, the development of array-based strategies to evaluate gene expression, and the evolution of high-throughput sequencing and screening of drug libraries, the stage is set to make new insights into the pathogenesis of IPF and evolve new therapeutic approaches to the treatment of this disorder (11).

Original languageEnglish
Title of host publicationIdiopathic Pulmonary Fibrosis
PublisherCRC Press
Pages733-760
Number of pages28
ISBN (Electronic)9780203913444
ISBN (Print)9780824740733
Publication statusPublished - 1 Jan 2003

Fingerprint

Idiopathic Pulmonary Fibrosis
Therapeutics
Preclinical Drug Evaluations
Human Genome
Natural History
Lung Diseases
Libraries
Cell Biology
Molecular Biology
Cell Culture Techniques
Direction compound
Technology
Gene Expression
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Heguy, A., Kaplan, R., & Crystal, R. (2003). Future directions in genetic strategies for understanding and treating idiopathic pulmonary fibrosis. In Idiopathic Pulmonary Fibrosis (pp. 733-760). CRC Press.

Future directions in genetic strategies for understanding and treating idiopathic pulmonary fibrosis. / Heguy, Adriana; Kaplan, Rana; Crystal, Ronald.

Idiopathic Pulmonary Fibrosis. CRC Press, 2003. p. 733-760.

Research output: Chapter in Book/Report/Conference proceedingChapter

Heguy, A, Kaplan, R & Crystal, R 2003, Future directions in genetic strategies for understanding and treating idiopathic pulmonary fibrosis. in Idiopathic Pulmonary Fibrosis. CRC Press, pp. 733-760.
Heguy A, Kaplan R, Crystal R. Future directions in genetic strategies for understanding and treating idiopathic pulmonary fibrosis. In Idiopathic Pulmonary Fibrosis. CRC Press. 2003. p. 733-760
Heguy, Adriana ; Kaplan, Rana ; Crystal, Ronald. / Future directions in genetic strategies for understanding and treating idiopathic pulmonary fibrosis. Idiopathic Pulmonary Fibrosis. CRC Press, 2003. pp. 733-760
@inbook{cda75ebd336d44c6bc28d95ee51b4187,
title = "Future directions in genetic strategies for understanding and treating idiopathic pulmonary fibrosis",
abstract = "Insights into the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the strategies for treatment of this disorder have evolved over the past 30 years. In the pregenetic era, prior to the early 1970s, the pathogenesis and treatment of IPF was based on classic clinical and pathological assessments. In this period, the disease was defined on a clinical level, with the natural history, clinical presentation, blood chemistry, radiographic features, and morphology of the disorder understood (1–5). In what can be called the early genetic era, from the late 1970s to the present, as the newly developed technologies of mammalian molecular biology, cell biology, and culture were applied to lung disease, IPF was understood to be an inflammatory disorder with superimposed dysfunction of lung repair mechanisms, and new approaches to therapy were developed (6–10). In the current genetic era, with the sequencing of the human and murine genomes, the development of array-based strategies to evaluate gene expression, and the evolution of high-throughput sequencing and screening of drug libraries, the stage is set to make new insights into the pathogenesis of IPF and evolve new therapeutic approaches to the treatment of this disorder (11).",
author = "Adriana Heguy and Rana Kaplan and Ronald Crystal",
year = "2003",
month = "1",
day = "1",
language = "English",
isbn = "9780824740733",
pages = "733--760",
booktitle = "Idiopathic Pulmonary Fibrosis",
publisher = "CRC Press",

}

TY - CHAP

T1 - Future directions in genetic strategies for understanding and treating idiopathic pulmonary fibrosis

AU - Heguy, Adriana

AU - Kaplan, Rana

AU - Crystal, Ronald

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Insights into the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the strategies for treatment of this disorder have evolved over the past 30 years. In the pregenetic era, prior to the early 1970s, the pathogenesis and treatment of IPF was based on classic clinical and pathological assessments. In this period, the disease was defined on a clinical level, with the natural history, clinical presentation, blood chemistry, radiographic features, and morphology of the disorder understood (1–5). In what can be called the early genetic era, from the late 1970s to the present, as the newly developed technologies of mammalian molecular biology, cell biology, and culture were applied to lung disease, IPF was understood to be an inflammatory disorder with superimposed dysfunction of lung repair mechanisms, and new approaches to therapy were developed (6–10). In the current genetic era, with the sequencing of the human and murine genomes, the development of array-based strategies to evaluate gene expression, and the evolution of high-throughput sequencing and screening of drug libraries, the stage is set to make new insights into the pathogenesis of IPF and evolve new therapeutic approaches to the treatment of this disorder (11).

AB - Insights into the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the strategies for treatment of this disorder have evolved over the past 30 years. In the pregenetic era, prior to the early 1970s, the pathogenesis and treatment of IPF was based on classic clinical and pathological assessments. In this period, the disease was defined on a clinical level, with the natural history, clinical presentation, blood chemistry, radiographic features, and morphology of the disorder understood (1–5). In what can be called the early genetic era, from the late 1970s to the present, as the newly developed technologies of mammalian molecular biology, cell biology, and culture were applied to lung disease, IPF was understood to be an inflammatory disorder with superimposed dysfunction of lung repair mechanisms, and new approaches to therapy were developed (6–10). In the current genetic era, with the sequencing of the human and murine genomes, the development of array-based strategies to evaluate gene expression, and the evolution of high-throughput sequencing and screening of drug libraries, the stage is set to make new insights into the pathogenesis of IPF and evolve new therapeutic approaches to the treatment of this disorder (11).

UR - http://www.scopus.com/inward/record.url?scp=85057918025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057918025&partnerID=8YFLogxK

M3 - Chapter

SN - 9780824740733

SP - 733

EP - 760

BT - Idiopathic Pulmonary Fibrosis

PB - CRC Press

ER -